Patient 5: Cancer-free at six months

Patient 5 tolerated the single-dose treatment well, and has demonstrated no tumor recurrence or presence of disease at the 180 day clinical and cystoscopy assessment. This patient has successfully achieved the primary, secondary and exploratory endpoints. More details can be found in the press release.